Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

Shares of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) were trading at $1.65, down $2.45, or 59%, after the company disclosed phase II results from the Bestow trial testing tegoprubart, which targets ...

MIT researchers discovered that the genome’s 3D structure doesn’t vanish during cell division as previously thought. Instead, tiny loops called microcompartments remain (and even strengthen) while ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no ...

A cell that has just started interphase with four chromosomes will duplicate these chromosomes during the S phase, resulting ...

Research has shown how Alzheimer's disrupts circadian rhythms in certain brain cells, altering the activity of hundreds of genes.

(A) The Incucyte® Apoptosis Assay allows automated imaging and quantitative analysis of every well of a 96/384-well plate, ...

Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of two abstracts for poster presentations at ...

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...